Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Gynecol Oncol. 2015 Jan;136(1):82-6. doi: 10.1016/j.ygyno.2014.10.025. Epub 2014 Oct 31.
To compare the efficacy between acupuncture and ondansetron in the prevention of delayed chemotherapy induced nausea and vomiting (CINV).
70 patients were randomized to receive either 1) acupuncture at P6 point before chemotherapy infusion or 2) ondansetron 8 mg intravenously 30 min before chemotherapy infusion in their first cycle with cross-over of antiemetic regimen in the consecutive cycle. All patients received dexamethasone 5mg orally twice a day for 3 days. Patients were given additional does of ondansetron 4 mg orally every 12h if they experienced emesis. Emetic episode, severity of nausea score of 0-10 and adverse events were recorded. Complete response was defined as no nausea, no vomiting and no requirement of additional antiemetic drugs. FACT-G scale was used to evaluate quality of life (QOL) 7 days after each cycle of chemotherapy.
The acupuncture group had a significantly higher rate of complete response in the prevention of delayed CINV (52.8% and 35.7%, P = 0.02). Compared to another group, the acupuncture group reported significantly lower delayed nausea (45.7% and 65.7%, P = 0.004), nausea score (P < 0.001) and fewer dosages of additional oral ondansetron (P = 0.002). Adverse effects were also significantly lower in the acupuncture group with less frequent constipation (P = 0.02) and insomnia (P = 0.01). Overall FACT-G scores were significantly higher in the acupuncture group.
Acupuncture is effective in preventing delayed CINV and in promoting better QOL. With fewer adverse effects, it may be used as an alternative treatment option for CINV.
比较针刺与昂丹司琼预防化疗引起的迟发性恶心和呕吐(CINV)的疗效。
70 例患者随机分为两组,第 1 周期分别接受 1)针刺化疗前 P6 点或 2)化疗前 30 分钟静脉内昂丹司琼 8mg,连续周期交叉使用止吐方案。所有患者均接受地塞米松 5mg,每日口服 2 次,连用 3 天。如果出现呕吐,患者给予昂丹司琼 4mg 口服,每 12 小时 1 次。记录呕吐发作、恶心严重程度评分(0-10 分)和不良反应。完全缓解定义为无恶心、无呕吐且无需额外使用止吐药物。化疗后第 7 天采用 FACT-G 量表评估生活质量(QOL)。
针刺组预防迟发性 CINV 的完全缓解率明显较高(52.8%和 35.7%,P=0.02)。与另一组相比,针刺组迟发性恶心(45.7%和 65.7%,P=0.004)、恶心评分(P<0.001)和额外口服昂丹司琼剂量(P=0.002)均明显较低。针刺组不良反应也明显较低,便秘(P=0.02)和失眠(P=0.01)发生频率较低。针刺组的总体 FACT-G 评分明显较高。
针刺可有效预防迟发性 CINV,提高生活质量。不良反应少,可作为 CINV 的替代治疗选择。